Navigation Links
St. Jude test of bird flu vaccine proves successful

A commercially developed vaccine has successfully protected mice and ferrets against a highly lethal avian influenza virus, according to the investigator who led the study at St. Jude Children's Research Hospital. The vaccine was developed by Vical Incorporated in San Diego, California.

This finding, coupled with results of previous studies that showed protection against multiple human influenza strains, suggests that such a vaccine would protect humans against multiple variants of the bird and human influenza viruses, according to Richard Webby, Ph.D., assistant member of Infectious Diseases at St. Jude. Such a vaccine could protect humans against an H5N1 "bird flu" virus that mutates so that it adapts to humans and can readily spread from person to person, Webby said. Flu experts and public health officials fear that such an H5N1 variant would trigger a human pandemic (worldwide epidemic).

Webby is scheduled to present the findings of this study at the U.S. Public Health Service Professional Conference in Denver, Colo., May 3 at 12:30 pm EDT.

The investigators used two versions of Vical's multi-component, DNA-based vaccine in the studies. One vaccine was directed against three viral proteins: NP and M2, which are "conserved" proteins that generally do not mutate quickly and therefore, are slow to avoid immune responses triggered by the vaccine; and H5, a "variable" protein on the surface of the bird and human flu viruses that is critical to their ability to infect cells. This variable protein is known to mutate readily, thereby foiling previous immune responses it triggered--whether due to natural exposure or vaccination. The other version of the vaccine contained only the two conserved viral proteins.

In the St. Jude study, the full, three-component vaccine (H5, NP and M2) provided complete protection in mice against lethal challenges with a highly virulent (Vietnam/1203/2004) H5N1 avian influenza virus. Moreover, other studies sho wed that a smaller version of the vaccine containing only the NP and M2 components provided significant protection against several strains of human influenza virus as well as the H5N1 "bird flu" strain.

"Such cross-protection against bird and human influenza is considered by researchers to be the 'Holy Grail' of flu vaccines," Webby said. "By stimulating immune responses against targets not likely to mutate, the vaccine could trigger an immune defense against a broad range of variants of the virus.

"Even if the bird flu virus mutates so it becomes adapted to humans, this kind of cross protection will allow the immune system to track and attack such an emerging new variant without missing a beat," Webby said. "We wouldn't have to wait to start developing a vaccine against it until after the original virus mutated."

Webby's team showed that all mice and ferrets that received the DNA vaccine survived the challenge with the virulent H5N1 strain, while those that received a "blank" vaccine control did not survive. The vaccine also prevented weight loss in all animals challenged with the virulent virus, suggesting that the vaccine might also protect humans against serious flu-related sickness.

The studies included 16 mice or six ferrets in each vaccine or control group. The DNA vaccines targeted NP and M2--with and without the H5 avian influenza virus surface protein. All test DNA vaccines were formulated with the company's VaxfectinTM adjuvant. An adjuvant is an additive administered with a vaccine that has little effect by itself, but improves the response of the immune system to the vaccine.


Source:St. Jude Children's Research Hospital

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:

(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Muncie, IN (PRWEB) , ... November 25, 2015 ... ... Aeronautics (AMA) and the Organization of Black Aerospace Professionals (OPBAP) has been formalized ... Mathewson and other AMA team leaders met with OPBAP leaders Capt. Karl Minter ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology: